E-Cat
The E-CAT system is a web-based government contract vehicle created by the Defense Logistics Agency (DLA) for streamlined procurement of medical supplies to the Department of Defense.
prod:prod_dcx-login
Government Partner Hub
Cepheid prides itself on government collaboration for its molecular diagnostic solutions and is privileged to support its government partners.
A Proud Heritage of Government Collaboration
1996
Founding with support from
DARPA and DoD
Founded in 1996 with technologies developed in part with funding from DARPA and DoD, Cepheid has proudly partnered with the Federal Government for more than two decades.
2004
USPS Selects Cepheid to develop Anthrax test
Integrated sample preparation, amplification, and detection for deployment in U.S. Postal Service sorting offices.
2007
Awarded Multiple GSA Contract
Cepheid has held a Multiple Award Schedule contract with GSA since 2007, which remains in effect today. Since 2018, Cepheid has been a member of the Medical CBRN Defense Consortium, which supports DoD’s medical, pharmaceutical, and diagnostic requirements.
2018
Cepheid becomes Medical
CBRN Defense Consortium member
Since 2018, Cepheid has been a member of the Medical CBRN Defense Consortium, which supports DoD’s medical, pharmaceutical, and diagnostic requirements.
2021
Cepheid develops Xpert® Xpress SARS-CoV-2/Flu/RSV test partnering with DoD and BARDA
For detection and differentiation of SARS-CoV-2, Flu A, Flu B, and RSV.
30 Million
Cepheid tests in Government Health Facilities
+18 Million
Tests at United States Postal Services (USPS) locations
A range of innovative solutions ideal for our government partners
How We Help
Cepheid provides seamless access to the highest caliber diagnostic tools
Cepheid offers Federal Government customers purchasing convenience. All Federal Government customers may purchase instruments through Cepheid’s GSA MAS Contract. DoD customers may purchase instruments, tests, and other consumables through Cepheid’s ECAT Contract. VA customers may purchase instruments, tests, and other consumables through Blanket Purchase Agreements in place with VISNs. Cepheid’s products and services are also available through open-market purchasing. The links below provide additional information concerning Cepheid’s Federal Government contracts.
Contacts for Government Partners
Service Agreements
service.agreements@cepheid.com
Finance & Accounts Receivable
accounts.receivable@cepheid.com
Redeploy an Instrument
techsupport@cepheid.com
Ordering Information
order.management@cepheid.com
Testing in 3 Easy Steps: Sample-In, Answer-Out Technology
1
Insert swab into sample reagent vial and break
2
Transfer sample to cartridge
3
Insert cartridge and start test
Educational Materials
VA-Wide, Multicenter Verification Study of the Cepheid Xpert SARS-CoV-2 Assay
VA-Wide, Multicenter Verification Study of the Cepheid Xpert SARS-CoV-2 Assay
More...
Case Study: Decentralized Molecular Influenza Testing at Sanford Health
Sioux Falls, S.D.-based Sanford Health is an integrated health system with 44 medical centers and 482 clinics in nine states. To provide a consistent, high-quality patient experience, regardless of the facility a patient accessed, Sanford Health wanted a standardized solution for influenza testing. Prior to seeking standardization, Sanford Health had five different flu test methods via multiple vendors.
Sanford Health was looking for a technology that was rapid, accurate, easy-to-use and had a broad test menu with the potential to bring molecular testing to all sites, whether large or small, urban or rural.
A comprehensive evaluation process comparing three different molecular systems led Sanford Health to select Cepheid's platform. Key criteria included test performance, workflow, test menu, scalability and financial considerations. Following this evaluation, Sanford Health has implemented Cepheid's rapid molecular testing platform at 70 sites. "Decentralized flu testing can be achieved by using the right technology and vendor partnership," said Jody Thompson, MD, Sanford Health's molecular technical director.
See the full case study about Sanford Health's experience implementing decentralized molecular influenza testing.
More...
The Evolution of Molecular Diagnostics
November 21, 2022 – The COVID-19 pandemic has heightened public awareness about molecular diagnostics. While PCR testing has been the cornerstone of molecular diagnostics for years, there are a wide variety of molecular diagnostic solutions that provide faster results than traditional PCR-based methods. However, these solutions may not provide the same level of reliability and accuracy as PCR tests which analyze the presence of the actual virus’ genetic material with high sensitivity and are the most effective means of detecting active infection.
“When sick patients come in the hospital, you want the most sensitive test, and that’s a PCR test,” said Dr. Dave Persing, Chief Medical and Technology Officer for Cepheid, a molecular diagnostics company based in Sunnyvale, Calif. “You don’t want to miss a case and then find out later that the patient is positive for COVID-19. Having a sensitive test at admission is important.”
Dr. Persing continues, “In the past, molecular testing made sacrifices in sensitivity and performance in exchange for speed. But today, Cepheid’s combination of best-in-class laboratory quality accuracy along with speed is unique.”
“We were engaged early on after the anthrax scare to build a test cartridge that could test the mail for anthrax,” Dr. Persing explained. “In 2009, we built a test for H1N1 influenza and in 2014, we built a test for Ebola.”
Today, Cepheid’s Xpert® Xpress CoV-2/Flu/RSV plus (“4-plex plus”) PCR test provides actionable, rapid respiratory results to meet the challenges of the ongoing COVID-19 pandemic. It rapidly detects the presence of the SARS-CoV-2 virus, including emerging variants. In addition, it detects and differentiates between Influenza A, Influenza B, RSV and SARS-CoV-2 viruses, as well as identifying potential co-infections during the respiratory season.
Read more in the latest issue of Journal of Healthcare Contracting.
More...
Glossary of Terms
| BARDA | Biomedical Advanced Research and Development Authority | |
| CBRN | Chemical, biological, radiological and nuclear defense | |
| CDC | Centers for Disease Control and Prevention | |
| DHA | Defense Health Agency | |
| DLA | Defense Logistics Agency | |
| DoD | Department of Defense | |
| E-Cat | Electronic Cataloging | |
| DARPA | Defense Advanced Research Projects Agency | |
| FSS | Federal Supply Schedule | |
| GSA | General Services Administration | |
| MTA | Military Treatment Facility | |
| VA | Veterans Administration |
IVD. In Vitro Diagnostic Medical Device. May not be available in all countries
Cepheid®, the Cepheid logo, GeneXpert®, and Xpert® are trademarks of Cepheid, registered in the U.S. and other countries. All other trademarks are the property of their respective owners.